Cantourage
Cantourage UK Reinforces Influential Status in UK’s Medical Cannabis Market, by Announcing New Partnership with Premier Craft Canadian Cultivator, LOT420
LONDON, June 15, 2023 /PRNewswire/ — Cantourage UK, the London based subsidiary of publicly listed Cantourage Group SE, is excited to announce a strategic partnership with LOT420, a highly regarded cultivator of medical cannabis based in Montreal, Canada. This collaboration aims to set a new bar for quality, consistency, and continuity in patient care within the UK medical cannabis market.
LOT420 is a licensed cannabis producer with a total area of approximately 2,000 m², a team of over 30 experienced cannabis growers are dedicated to cultivating select cannabis strains. Through years of experience and optimisation, the company has developed proven methods that consistently deliver high-quality products. Patients in the UK will now have access to internationally recognised, craft-cultivated genetics, promoting a shift towards legally obtained, high-quality medical cannabis, providing patients a trusted legal option, without jeopardising their livelihoods.
Gabriel Newman, Co-Founder & CEO of Cantourage UK, commented: “In a dynamic market that continually calls for higher standards and patient-centric approaches, our partnership with LOT 420 signifies our commitment to patients who are seeking relief from their persistent ailments. Through collaboration with experienced cultivators like LOT 420, we strengthen our resolve to deliver accessible, top-tier medical cannabis products. The launch of LOT 420’s product range in Germany has received a resounding reception from patients and we are delighted to announce that the first of many upcoming varieties are available to UK patients”.
“With the help of our partners at Cantourage, LOT420 has been able to establish itself within the German medical market as one of the premium producers offering high-quality medicine,” said Stefan Macdonald, CEO of LOT420. “We are excited to announce that as of today, via Cantourage, medical patients in the UK will be able to be prescribed LOT420’s premium cannabis flowers for their treatment.”
Leveraging this exceptional product and their deep-rooted commitment to top-tier standards, Cantourage Group SE is manufacturing and distributing LOT420’s non-irradiated medical cannabis across Europe and now, in the UK.
About Cantourage UK
Cantourage UK is a joint venture established in January 2021 between Cantourage Group SE, a publicly listed European cannabis company, and NICE Partners, a London-based firm founded in 2019 by Benjy Cuby, Gabriel Newman, Joshua Cuby and Niall Ivers. Cantourage UK is committed to meeting the needs of patients across the UK by importing high-quality medical cannabis products from around the world.
About LOT420
LOT420 is a licensed cannabis producer located Montreal, Canada. With their individual expertise for each phase of cultivation, the growers focus with great passion on the cultivation of selected cannabis varieties. The conviction to work in the service of nature, highest care as well as the self-declared company goal to offer only the best products on the market are at the core of their actions. Methods that have been improved over the years and constant process optimisations also ensure the consistently high quality of the products.
Learn more: https://www.lot420.com/
Contact: Name: Neon Rocks PR Agency
Contact Name: Natasha Hassani
Contact detail: natasha@neonrockspr.com
Photo – https://mma.prnewswire.com/media/2100364/Cantourage_press_release_artwork.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/cantourage-uk-reinforces-influential-status-in-uks-medical-cannabis-market-by-announcing-new-partnership-with-premier-craft-canadian-cultivator-lot420-301851759.html
View original content to download multimedia:
Cantourage
Cantourage UK Partners with Portocanna to Improve Affordable Medical Cannabis Access in the UK
The Partnership Paves the Way for Consistent, High-Quality Affordable Medical Cannabis Supply for Patients
LONDON, June 16, 2023 /PRNewswire/ — Leading London-based medical cannabis company Cantourage UK and Portugal-based manufacturer Portocanna have announced an exclusive partnership. This collaboration aims to deliver affordable high-quality CBPM’s to patients in the UK, fulfilling an important unmet need in the market.
Portocanna, located in Santarém, Portugal, maintains a firm commitment to leveraging the health benefits of cannabis. Their dedicated team of professional’s work with carefully selected cultivators to ensure delivery of high-quality cannabis products, consistently.
Joshua Cuby, Co-Founder & Chief Sales Officer of Cantourage UK stated “In Cantourage UK, our focus has always been on delivering quality, consistent genetics and CBPMs. We’ve found a like-minded partner in Portocanna who shares this philosophy. Our partnership signifies our commitment to step up for the patients who need us most. We look forward setting new benchmarks in the UK and Channel island’s medical cannabis sector.”
This partnership marks Portocanna’s inaugural entry into the UK and Channel Islands market, following their success in Germany.
“We see this partnership as a crucial step in our mission to become a reliable provider of pharma-grade medical cannabis products,” Amit Edri, Co-Founder, Chairman & CEO of Portocanna. “We trust Cantourage UK to enable us to fulfil our vision of consistent, reliable access to top-grade medical cannabis products for patients.”
Portocanna will provide:
- EU-GMP certification for flower and extract production.
- Selection of 25 registered cannabis strains.
- Substantial processing capacity within the same facility.
- The largest medical cannabis logistics centre in the EU.
- A state-of-the-art in-house laboratory for quality control.
- An internal Biotech R&D team.
“Both parties are proud about this partnership, a move that aligns with our commitment to improve patient access to affordable high-quality medical cannabis in the UK and Channel Islands,” said Amit.
This collaboration between Cantourage UK and Portocanna will play a pivotal role in shaping the UK’s medical cannabis landscape, securing more reliable access to quality medical cannabis for UK patients.
About Cantourage UK
Cantourage UK is a joint venture established in January 2021 between Cantourage SE, a publicly listed European cannabis company, and NICE Partners, a London-based firm founded in 2019 by Benjy Cuby, Gabriel Newman, Joshua Cuby and Niall Ivers. Cantourage UK is committed to meeting the needs of patients across the UK by importing high-quality medical cannabis products from around the world.
About Portocanna
Founded in 2019, Portocanna is committed to delivering the best nature has to offer in an accessible, trustworthy, and consistent way. We believe that cannabis has arrived to disrupt the future of medicine. We aim to build a high-quality, valuable product portfolio and create a network of partnerships to release the best products in the market as branded products, or under partnerships with strategic distributors.
Neon Rocks PR Agency
Natasha Hassani
natasha@neonrockspr.com
Photo – https://mma.prnewswire.com/media/2103081/Cantourage_UK_1.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/cantourage-uk-partners-with-portocanna-to-improve-affordable-medical-cannabis-access-in-the-uk-301852118.html
-
Cannabis2 weeks agoHemp, Inc.’s Creative Visionary Consultant, Bruce Perlowin, to be Interviewed Live on the Quantum Energy, Health, and Information Call Today
-
Cannabis2 weeks ago
New Report Reveals Pre-Rolls Emerge As The Second-Largest Product Category In Canada, Poised to Overtake Flower as the Leading Category
-
Cannabis2 weeks agoIM Cannabis Announces CFO Departure
-
Cannabis2 weeks agoCannabidiol (CBD) Market Size ($ 15978.16 Billion by 2030 at CAGR of 18.36% CAGR) – which is Booming Strong Growth in the Globe till 2030
-
Cannabis2 weeks agoEndexx Announces Amended Consolidated 10-Q/A: Quarterly Report for The Quarter Ending March 31, 2023, Increasing Year-Over-Year 1013%
-
Cannabis2 weeks agoLegal Cannabis Commercialization Bolsters Vacuum Oven Demand; Essential Role in Processing Extracts and Enhancing Safety Recognized
-
Cannabis2 weeks agoCBD Skin Care Market Size is projected to reach USD 6466.43 million by 2030, growing at a CAGR of 32.15%: Straits Research
-
Cannabis1 week agoNew to The Street Announces its Five Corporate Interviews, airings on Newsmax and FOX Business Network